Clinical Trials Directory

Trials / Completed

CompletedNCT00928252

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Queen's Medical Center · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory) metastatic prostate cancer.

Detailed description

Patients who meet eligibility criteria and are enrolled will undergo whole-body imaging with 18F-choline PET/CT at 3 time points during the course of treatment that is indicated for castrate resistant prostate cancer. The 1st PET/CT scan is performed at baseline before treatment initiation. The 2nd and 3rd scans are performed at two other treatment-releated timepoints or at approximately 1 month and 3 months after treatment initiation. Change in lesion 18F-choline uptake from baseline measured at each time point will be determined. Cancer 18F-choline uptake will be evaluated as a marker of therapeutic response in comparison to PSA response and symptom scores. Treatment-related changes in tumor 18F-choline uptake occur will be studied after the second and third PET scans to determine the acuity by which changes in tumor 18F-choline uptake can be expected following specific treatments for castrate-resistant prostate cancer. The study evaluates a diagnostic intervention and the treatments themselves are not considered part of the investigation. All treatment decisions will be made independent of the study and must be deemed clinically-warranted by a treating physician.

Conditions

Interventions

TypeNameDescription
DRUGIV fluorine-18 labeled methylcholine before PET/CTIntervention at pre-treatment, and at two timepoints post treatment intiation.

Timeline

Start date
2009-06-01
Primary completion
2016-06-01
Completion
2016-06-01
First posted
2009-06-25
Last updated
2017-08-14
Results posted
2017-08-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00928252. Inclusion in this directory is not an endorsement.